← Leaderboards
Ho Yin Lo
Qx Therapeutics, Inc.
$963,014
Attributed
$2,295,760
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2019–23$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$2,295,760 · 2
By mechanism
R44$1,999,119 · 1
R43$296,641 · 1
Top collaborators
- Anita Bellail2 shared
- Chunhai Charlie Hao2 shared
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponseToxicologyLungProteinsRodentSolubilityDrug KineticsIn VivoPermeabilityPreclinical DevelopmentClinical TrialsCellsSmall Business Innovation Research GrantSmall MoleculeDiagnosisDoseFormulationIn VitroMedicalOralPharmaceutical PreparationsPharmacologyCessation Of LifeTreatment Efficacy
Grant awards (3)
Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer$979,536
R44 · FY2023 · CA
Development of SUMO1 small molecule degraders as the first-in-class anticancerdrugs for metastatic colorectal cancer$1,019,583
R44 · FY2022 · CA
Development of Small Molecules MAP3K2/3 Inhibitor for Treatment of Acute Lung Injury$296,641
R43 · FY2019 · HL · contact PI